Drug Profile

Research programme: targeted siRNA therapeutics - Bridge Medicines/Memorial Sloan Kettering Cancer Center

Alternative Names: fCNT/siMep1b; fCNT/siRNA; fCNT/siTrp53; Functionalised, single walled carbon nanotube-targeted siRNA therapeutics

Latest Information Update: 28 Aug 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Aug 2022 No recent reports of development identified for preclinical development in Acute kidney injury in USA (Parenteral)
23 Jul 2018 Bridge Medicines and Memorial Sloan Kettering Cancer Center agree to co-develop fCNT-targeted siRNA in USA for Acute kidney injusry
23 Jul 2018 Preclinical trials in Acute kidney injury in USA (Parenteral) prior to July 2018

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com